Viridian Therapeutics, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Viridian Therapeutics, Inc. on May 17, 2021, covering the event date of May 14, 2021. The Company is a Delaware corporation with principal executive offices in Boulder, Colorado, and its common stock trades on The Nasdaq Stock Market under the symbol "VRDN".
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity metrics. This report focuses exclusively on a corporate governance event.
Material Changes
On May 14, 2021, Jason Leverone resigned as the Chief Financial Officer and principal financial and accounting officer of the Company. This departure represents a material change in the Company's principal officers.
Management Commentary and Contingencies
In connection with Mr. Leverone's resignation, the Company agreed to provide severance benefits equivalent to those arising from an involuntary not-for-cause termination under his employment agreement dated December 2, 2016, and his bonus agreement dated September 14, 2020. The report does not contain forward-looking guidance, risk factors, or discussion of unusual items beyond this executive departure.
Investor Verification Checklist
- Verify the specific financial terms and total payout amount of the severance package for the departing CFO.
- Confirm the timeline and status of the appointment of a new Chief Financial Officer.
- Review the Company's most recent 10-Q or 10-K filing for current liquidity and cash runway, as this 8-K does not contain financial data.